Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oldenburg, Johannes
NCT05936580: Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery	Recruiting	4	28	Europe, US, RoW	Nuwiq	Octapharma	Hemophilia A	12/25	12/25
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications	Active, not recruiting	N/A	550	US	Standard care with blood and urine sample collection	Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum	Factor IX Deficiency	06/19	12/21
PedNet, NCT02979119: The European Paediatric Network for Haemophilia Management ( Registry)	Recruiting	N/A	4000	Europe, Canada, RoW		PedNet Haemophilia Research Foundation, Lund University Hospital	Factor VIII Deficiency, Factor IX Deficiency	12/29	12/29
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A	Active, not recruiting	N/A	207	Europe, US, RoW	ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855	Baxalta now part of Shire	Hemophilia A	02/30	02/30
Protect-NOW, NCT03695978: Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia a Patients	Recruiting	N/A	200	Europe, Canada, US, RoW		Octapharma	Haemophilia a	06/30	06/30